Merck KGaA signs another AI dealMerck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative Share XMerck KGaA signs another AI dealhttps://pharmaphorum.com/news/merck-kgaa-signs-another-ai-deal/
Merck KGaA admits to ‘challenging’ 2018, as currencies hit salesGermany’s Merck KGaA has described 2018 as a “challenging” year, which saw profits hit by currency headwinds and Share XMerck KGaA admits to ‘challenging’ 2018, as currencies hit saleshttps://pharmaphorum.com/news/merck-kgaa-admits-to-challenging-2018-as-currencies-hit-sales/
GSK bolts-on immuno-oncology candidate with €3.7bn Merck dealGlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an Share XGSK bolts-on immuno-oncology candidate with €3.7bn Merck dealhttps://pharmaphorum.com/news/gsk-bolts-on-immuno-oncology-candidate-with-e3-7bn-merck-deal/
Vertex licenses back CRISPR compounds from German MerckUS pharma Vertex has licensed back two gene editing compounds that can be used with CRISPR/Cas9 technology, from Share XVertex licenses back CRISPR compounds from German Merckhttps://pharmaphorum.com/news/vertex-licenses-back-crispr-compounds-from-german-merck/
Merck KGaA signs China digital health deal with TencentGermany’s Merck KGaA has signed a collaboration with Tencent to develop digital healthcare services in China. Darmstadt-based Merck’s Share XMerck KGaA signs China digital health deal with Tencenthttps://pharmaphorum.com/news/merck-kgaa-signs-china-digital-health-deal-with-tencent/
Merck KGaA links with AI firm to iron out side-effects during R&DGermany’s Merck KGaA has begun a licensing agreement with Canadian pharma R&D company Cyclica using artificial intelligence (AI) Share XMerck KGaA links with AI firm to iron out side-effects during R&Dhttps://pharmaphorum.com/news/merck-kgaa-links-with-ai-firm-to-iron-out-side-effects-during-rd/
P&G completes acquisition of Merck KGaA’s OTC divisionProcter & Gamble (P&G) has completed its acquisition of Merck KGaA’s Consumer Health business, in a move it Share XP&G completes acquisition of Merck KGaA’s OTC divisionhttps://pharmaphorum.com/news/pg-completes-acquisition-merck-kgaas-otc-division/
Merck KGaA’s bold new approach to cancer immunotherapyGermany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer Share XMerck KGaA’s bold new approach to cancer immunotherapyhttps://pharmaphorum.com/views-analysis-oncology/merck-kgaas-bold-new-approach-to-cancer-immunotherapy/
First line kidney cancer could get crowded as Merck KGaA/Pfizer join the frayCompetition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO Share XFirst line kidney cancer could get crowded as Merck KGaA/Pfizer join the frayhttps://pharmaphorum.com/news/first-line-kidney-cancer-inlyta-bavencio/
